Target intelligence / Profile preview

STARD3 N-terminal like protein (STARD3NL)

Target
STARD3NL
Molecular classification
Other (membrane contact tether, membrane protein), START domain-containing protein family (StAR-related lipid transfer)
01

Overview

STARD3 N-terminal like protein (STARD3NL or MENTHO) is a membrane protein anchored to late endosomes that plays a role in creating membrane contact sites (MCS) between late endosomes and the endoplasmic reticulum (ER)[2]. It possesses a conserved FFAT (two phenylalanines in an acidic tract) motif that allows specific interaction with ER-resident VAP (vesicle-associated membrane protein-associated protein) family proteins, forming tethers that allow the apposition of endosomal and ER membranes[2]. This tethering alters organelle dynamics and is implicated in the regulation of endosomal tubulation. Unlike STARD3, STARD3NL does not show evidence of direct lipid (cholesterol) transfer or well-characterized roles as a canonical drug target, enzyme, transporter, or receptor[2]. It is best described as a structural protein contributing to inter-organelle communication and membrane organization. Notes and distinctions: - STARD3NL is distinct from STARD3: STARD3 is primarily involved in cholesterol transport and has been studied in the context of metabolic disorders and cancer; STARD3NL is mainly a tethering protein without direct sterol transport activity[2][3]. - No current evidence suggests direct therapeutic targeting, biomarker use, or relevance for drug action for STARD3NL.

Other names
STARD3 N-terminal-like proteinMENTHOUNQ855/PRO1864MGC3251MLN64 N-terminal domain homolog
02

Biological functions

Formation of membrane contact sites (MCS) between late endosomes and endoplasmic reticulum (ER)[2]Organelle tethering (late endosome–ER tether, via VAP interaction)[2]Modulation of endosome dynamics, specifically affecting endosomal tubule formation[2]Possibly involved in cholesterol membrane dynamics indirectly (as partner of STARD3)
03

Disease associations

Other (no direct, well-established disease association; STARD3—not STARD3NL—has been investigated in cancer such as breast cancer)[4]

Beyond the preview

Go deeper on STARD3 N-terminal like protein (STARD3NL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on STARD3 N-terminal like protein (STARD3NL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call